Depomed Announces Save the Date for 2016 Analyst and Investor Day

NEWARK, Calif., Jan. 27, 2016 -- Depomed, Inc. (NASDAQ:DEPO) today announced that it will hold an Analyst and Investor Day in New York City on Wednesday, March 23, 2016 from 9:00 a.m. ET – 11:30 a.m. ET (6:00 a.m. PT – 8:30 a.m. PT). Depomed’s President and Chief Executive Officer Jim Schoeneck and members of the company's management team will be joined by Joseph V. Pergolizzi, Jr., MD, an Adjunct Assistant Professor in the Department of Medicine at Johns Hopkins University School of Medicine in Baltimore, Maryland and an internationally recognized leader in the area of pain medicine and management. The event will provide a business overview as well as a review of the marketed and development-stage product pipeline.

Space is limited and attendance is by invitation only.  The presentations, as well as the question and answer session, will be webcast and will be accessible via the Investor Relations page of the Depomed website at www.depomed.com.  A recording of the webcast will be archived for 30 days.  Additional event details will be available closer to the event date.

About Depomed

Depomed is a leading specialty pharmaceutical company focused on enhancing the lives of the patients, families, physicians, providers and payors we serve through commercializing innovative products for pain and neurology related disorders. Depomed markets six medicines with areas of focus that include mild to severe acute pain, moderate to severe chronic pain, neuropathic pain, migraine and breakthrough cancer pain. Depomed is headquartered in Newark, California. To learn more about Depomed, visit www.depomed.com

Investor Contact:
Christopher Keenan
VP, Investor Relations and Corporate Communications
510-744-8000
[email protected]